World's Leading Imaging CRO Advances Melanoma Research
Boston, MA, January 25, 2018 -- WorldCare Clinical
(WCC), a leading provider of imaging services in Oncology clinical trials,
announced that it had commenced central review services on a fourth
international clinical trial to assess treatments for melanoma. These central
reviews are performed by teams of board-certified subspecialty trained
physicians who utilize WCC health informatics tools such as teledermatology,
teleradiology and digital pathology to optimize presentation of clinical trial
data for central independent reviewers.
Melanoma is the
most dangerous form of skin cancer and an active area of clinical trial
research. Each year, in the United States more than 87,000 people are diagnosis
with melanoma and approximately 10,000 people a year die from the disease.
Determining the efficacy of melanoma treatments requires an assessment of both
radiological and skin lesion severity. "Our teledermatology services
combine advanced photo analysis tools with expert photo reviews by experienced
melanoma dermatologists and melanoma oncologist from Harvard hospitals. This
combination results in maximizing sensitivity of lesion assessment and has been
instrumental in the FDA approval of a prior melanoma therapy," stated
Aaron Timm, CEO of WorldCare Clinical.
is a global imaging CRO that employs scientific expertise, innovative
technology, and operational excellence to maximize the precision and accuracy
of a blinded independent central review of Phase I – IV clinical trial data.
The company has worked with thousands of sites in more than 60 countries. WCC's
robust technology platform processes over 250 million images annually (CT, MRI,
X-Ray, Echo, US, PET). Originally founded in 1992 by the Massachusetts General
Hospital (MGH) Department of Radiology, WorldCare continues to maintain a
strategic relationship with the Harvard Hospital System as well as other
leading academic institutions.
information on WCC's services, please visit our website at www.wcclinical.com or contact: